Drug intelligence / Profile preview

BECC470

Development stage: Preclinical
Lead developer: University of Iowa
Modality: Small Molecules
Administration: Intranasal

Overview

BECC470 is a next-generation Toll-like receptor 4 (TLR4) agonist developed through bacterial enzymatic combinatorial chemistry (BECC). It is a structurally modified derivative of lipopolysaccharide (LPS) designed to preserve the potent anti-tumor immune activation of endotoxins while significantly reducing systemic toxicity. By selectively engaging TLR4, BECC470 induces a pro-inflammatory cytokine surge (including TNF⍺ and IFNγ) that promotes cytotoxic CD4+ T-cell-mediated immunity. It is currently being investigated in preclinical models for the treatment of pancreatic ductal adenocarcinoma (PDAC).

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on BECC470.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BECC470.

Explore the full profile